Novartis, ACZ885 – Impressive data in SJIA, but no meaningful commercial opportunity
Novartis today reported positive Phase 3 data on ACZ885 (canakinumab) in SJIA. The data is impressive but commercial opportunity would be limited as SJIA is a rare disease, while NVS may not be able to price the drug accordingly as Actemra which is already approved in this indication costs approximately $20000 or less depending on the weight. While if NVS chose to price ACZ885 at its existing annual cost ($100,000), it may not be able to get reasonable market share. We forecast $30m in incremental sales for ACZ885 in SJIA.
COMPANIES MENTIONED
Novartis
Novartis
